ZNF768: controlling cellular senescence and proliferation with ten fingers

IF 2.6 Q3 ONCOLOGY

Molecular and Cellular Oncology Pub Date : 2021-11-02 DOI:10.1080/23723556.2021.1985930

Romain Villot, Audrey Poirier, R. Devillers, A. Kolnoguz, S. Elowe, V. Manem, P. Joubert, Frédérick A. Mallette, M. Laplante

引用次数: 2

Abstract

ABSTRACT We recently identified Zinc-finger protein 768 (ZNF768) as a novel transcription factor controlling cell fate decision downstream of Rat sarcoma virus (RAS). We showed that ZNF768 depletion impairs cell cycle progression and triggers cellular senescence, while its overexpression allows cells to bypass oncogene-induced senescence. Elevated ZNF768 levels is common in tumors, suggesting that ZNF768 may help to escape cellular senescence, sustain proliferation and promote malignant transformation. Here, we discuss these recent findings and highlight key questions emerging from our work.

查看原文本刊更多论文

ZNF768：用十指控制细胞衰老和增殖

我们最近发现锌指蛋白768 (ZNF768)是一种新的转录因子，可控制大鼠肉瘤病毒(RAS)下游的细胞命运决定。我们发现，ZNF768缺失会损害细胞周期进程并触发细胞衰老，而其过表达允许细胞绕过癌基因诱导的衰老。ZNF768水平升高在肿瘤中很常见，提示ZNF768可能有助于细胞逃避衰老、维持增殖和促进恶性转化。在这里，我们讨论了这些最近的发现，并强调了我们工作中出现的关键问题。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Molecular and Cellular Oncology Biochemistry, Genetics and Molecular Biology-Cancer Research

CiteScore

3.20

自引率

0.00%

发文量

期刊介绍： For a long time, solid neoplasms have been viewed as relatively homogeneous entities composed for the most part of malignant cells. It is now clear that tumors are highly heterogeneous structures that evolve in the context of intimate interactions between cancer cells and endothelial, stromal as well as immune cells. During the past few years, experimental and clinical oncologists have witnessed several conceptual transitions of this type. Molecular and Cellular Oncology (MCO) emerges within this conceptual framework as a high-profile forum for the publication of fundamental, translational and clinical research on cancer. The scope of MCO is broad. Submissions dealing with all aspects of oncogenesis, tumor progression and response to therapy will be welcome, irrespective of whether they focus on solid or hematological neoplasms. MCO has gathered leading scientists with expertise in multiple areas of cancer research and other fields of investigation to constitute a large, interdisciplinary, Editorial Board that will ensure the quality of articles accepted for publication. MCO will publish Original Research Articles, Brief Reports, Reviews, Short Reviews, Commentaries, Author Views (auto-commentaries) and Meeting Reports dealing with all aspects of cancer research.